Time filter

Source Type

Liu Z.,Shenyang University | Liu Z.,Liaoning University | Su M.,Liaoning Provincial Tumor Hospital | Yu S.-C.,U.S. Center for Disease Control and Prevention | And 4 more authors.
Thoracic Cancer

The role of Chlamydia pneumoniae in the cause of lung cancer is controversial. In this study, we investigated the association between C. pneumoniae immunoglobulin (Ig) G antibodies and risk of lung cancer among non-smoking women. C. pneumoniae IgG antibody levels were compared between 192 adult Chinese women who met the diagnostic criteria of lung cancer and 90 healthy controls. C. pneumoniae IgG antibodies were tested with the use of an enzyme-linked immunosorbent assay. The prevalence of C. pneumoniae IgG seropositivity was 61.98% of cases and 28.89% of controls (P < 0.05). According to the results of the multiple logistic analysis model, the odds ratios for C. pneumoniae IgG antibody seropositivity, body mass index, and educational levels were 3.919 (P < 0.001), 0.731 (P= 0.274), and 1.646 (P= 0.069), respectively. C. pneumoniae infection may be a risk factor for lung cancer. © Tianjin Lung Cancer Institute and Blackwell Publishing Asia Pty. Ltd. Source

Hua X.-D.,Liaoning Provincial Tumor Hospital | He Z.-Y.,Liaoning Provincial Tumor Hospital
Chinese Journal of Oncology

Objective: To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer. Methods: From January 2006 to January 2010, 90 patients with recurrent hepatocellular carcinoma (HCC) were treated with MCT and TACE in our hospital. The treatment group received sorafenib + MCT + TACE, and the control group received MCT + TACE. Results: RR of the treatment group was 66.7% , which of the control group was 52.0% (P > 0.05). DCR was 83.3% in the treatment group and 64.5% in the control group (P < 0.05). Through a comparison of survival curves along with the extension of time, the survival rates of the two groups were decreased, but the treatment group (group 1) had a significantly higher one than the control group (group 2), with a statistically significant difference (P > 0.05). Conclusion: Sorafenib combined with MCT and TACE can improve the disease control rate and prolong the survival in patients with recurrent HCC. Source

Lin T.,Liaoning Provincial Tumor Hospital | Song C.,Liaoning Provincial Tumor Hospital | Wang H.,Liaoning Provincial Tumor Hospital
Chinese Journal of Clinical Oncology

Objective: This study aimed to observe the long-term effect of Pseudomonas aeruginosa preparation used in peritoneal injection of advanced colorectal cancer patients during surgery. Methods: A total of 83 colorectal cancer patients who received surgery between September 2006 and March 2008 were enrolled in this study. The patients were divided into two groups. Palliative resection and a 10 ml P. aeruginosa peritoneal injection were performed in 30 of 83 patients in the treatment group. Simple palliative resection was conducted in the other 53 patients, which comprised the control group. Both groups were then treated by regular chemotherapy and radiotherapy. Results: The follow-up visit was completed in 79 of 83 patients, with a high follow-up rate of 95.2%. No significant difference was found in the five-year overall survival time between the two groups (P=0.403). However, the five-year median survival time in the control group was only 13.9 ± 2.14 months, whereas that in the treatment group was 17.2 ± 2.12 months. Conclusion: Within a short period, peritoneal injection of P. aeruginosa during surgery could confer certain survival advantages for advanced colorectal cancer patients. However, the long-term effect of this therapy remains unknown. Source

Liu B.,Liaoning Provincial Tumor Hospital | Xu K.,Liaoning Provincial Tumor Hospital | Han H.-B.,Cancer Diagnosis and Treatment Center | Wang T.-L.,Liaoning Provincial Tumor Hospital | Song Y.-Q.,Liaoning Provincial Tumor Hospital
Chinese Journal of Cancer Prevention and Treatment

OBJECTIVE: To investigate the function of resveratrol (Res) and its mechanism in lung adenocarcinoma A549 cells. METHODS: A549 cells were treated with resveratrol at different concentretions for 24 h and the morphological change was observed by phase contrast microscope. Apoptosis features were observed by fluorescence microscope after nuclear DAPI staining. The proliferation of A549 cells was analyzed using methyl thiazolyl tetrazolium (MTT) assay. The expression of p53, Bax, Bcl-2 and Cleaved-Caspase3 after Res treatment in A549 cells was measured by Western blot. RESULTS: After Res treatment, we found that the interspace of A549 cells was decreased and granular material was found in nucleus. These changes were remarkably associated with the increase of resveratrol concentration. DAPI staining indicated that Res induces apoptosis in A549 cells. After treated with 25-200 μmol/L Res, the proliferation was markedly inhibited with a does dependent manner (25 μmol/L, 12.4%; 50 μmol/L, 21.6%; 100 μmol/L, 51.3%; 200 μmol/L, 89.7%), and IC50 was 98 μmol/L. Otherwise, after Res treatment, the expression of p53, Bax and Cleaved-Caspase3 protein was upregulated (r=0.930, P<0.001; r=0.874, P<0.001), Bcl-2 and the ratio of Bcl-2/Bax were downregulated (r=0.753, P=0.01). CONCLUSION: Resveratrol could inhibit the proliferation and induce apoptosis through p53 method in A549 cells, and the expression of Bax, Bcl-2 and Cleaved-Caspase3 participate in the apoptotic process modulated by resveratrol. Source

Wang W.,Liaoning Provincial Tumor Hospital | Zhang L.,Liaoning Provincial Tumor Hospital | Zheng K.,Liaoning Provincial Tumor Hospital | Zhang X.,Liaoning Provincial Tumor Hospital
Oncology Reports

MicroRNA-17-5p has been proven upregulated in many human malignancies and correlated with tumor progression. However, its expression and clinical significance in osteosarcoma is still unclear. Thus, the aim of the present study was to explore the effects of miR-17-5p in osteosarcoma tumorigenesis and development. The expression level of miR-17-5p was quantified by quantitative real-time reverse-transcriptasepolymerase chain reaction in primary osteosarcoma tissues and osteosarcoma cell lines. MTT, Transwell and matrigel assays were used to test the proliferation, migration and invasion of miR-17-5p transfection osteosarcoma cells, and a mouse model was used to investigate tumorigenesis. The expression levels of miR-17-5p in osteosarcoma tissues were significantly higher than those in corresponding non-cancerous bone tissues. In addition, miR-17-5p upregulation more frequently occurred in osteosarcoma specimens with advanced clinical stage, positive distant metastasis and poor response to neoadjuvant chemotherapy. After miR-17-5p transfection, cell proliferation, migration, invasion and tumorigenesis in the osteosarcoma cells were significantly promoted. We further demonstrated that BRCC2 is a direct target of miR-17-5p. These findings indicate that miR-17-5p may act not only as a novel diagnostic and prognostic marker, but also as a potential target for molecular therapy of osteosarcoma. Source

Discover hidden collaborations